Skip to main content
. 2019 Dec 11;14(4):500–508. doi: 10.5009/gnl19155

Table 2.

Treatment Outcomes of Variceal Bleeding (n=329)

Variable All HCC
(n=125, 38.0%)
LC without HCC
(n=204, 62.0%)
p-value
Initial hemostasis achievement 311 (94.5) 115 (92.0) 196 (96.1) 0.114
Rebleeding 191 (58.1) 75 (60.0) 116 (56.9) 0.576
Treatment failure or rebleeding within 5 day 33 (10.0) 22 (17.6) 11 (5.4) <0.001
Rebleeding within 6 wk 66 (20.1) 37 (29.6) 29 (14.2) 0.001
Death 186 (56.5) 97 (77.6) 89 (43.6) <0.001
In hospital mortality 40 (12.2) 25 (20.0) 15 (7.4) 0.001
Mortality within 6 wk 49 (14.9) 33 (26.4) 16 (7.8) <0.001
PRBC transfusion, unit 2 (1–4) 2 (1–4) 2 (1–4) 0.363
FFP transfusion, unit 0 (0–0) 0 (0–0) 0 (0–0) 0.574
Cirrhosis-related complications
Hepatic failure 26 (8.0) 18 (14.5) 8 (3.9) 0.001
Hepatorenal syndrome 16 (4.9) 11 (8.9) 5 (2.5) 0.009
Hepatic encephalopathy 43 (13.1) 22 (17.7) 21 (10.3) 0.055
Hospital stay, day 5 (3–9) 6 (3–13) 5 (3–8) 0.001

Data are presented as number (%) or median (interquartile range).

HCC, hepatocellular carcinoma; LC, liver cirrhosis; PRBC, packed red blood cell; FFP, fresh frozen plasma.